LiveBoost®Chronic Liver Disease Risk Calculation Software
Non-invasive diagnosis and staging of liver fibrosis based on clinical indicators such as serum biochemical index have been widely explored in the study of chronic liver diseases (CLD).
LiveBoost® selects some of the above-mentioned clinical indicators to build a new mathematical model. Since the indicators used are routine test items for liver diseases, subjects can quickly get the results of risk levels about fibrosis and cirrhosis in liver and auxiliary diagnostic reports by directly inputting data on LiveBoost®.
HMI has compared the results of liver biopsy of the subjects in its more than 10-year study based on more than 6,000 clinical samples. It has verified that the sensitivity and specificity of LiveBoost® for fibrosis and cirrhosis in liver are both higher than 90%, which means that LiveBoost® can directly show the parameters of liver function and accurately identify normal, mild, moderate and severe levels of fibrosis and cirrhosis in liver. LiveBoost® has been approved as a Class II medical device in China.
